NO971219D0 - Behandling og profylakse av pankreatitt - Google Patents

Behandling og profylakse av pankreatitt

Info

Publication number
NO971219D0
NO971219D0 NO971219A NO971219A NO971219D0 NO 971219 D0 NO971219 D0 NO 971219D0 NO 971219 A NO971219 A NO 971219A NO 971219 A NO971219 A NO 971219A NO 971219 D0 NO971219 D0 NO 971219D0
Authority
NO
Norway
Prior art keywords
pancreatitis
treatment
prophylaxis
troglitazone
prevention
Prior art date
Application number
NO971219A
Other languages
English (en)
Other versions
NO971219L (no
NO313179B1 (no
Inventor
Toshihiko Fujiwara
Hiroyoshi Horikoshi
Seiji Fukami
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO971219D0 publication Critical patent/NO971219D0/no
Publication of NO971219L publication Critical patent/NO971219L/no
Publication of NO313179B1 publication Critical patent/NO313179B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catching Or Destruction (AREA)
NO19971219A 1996-03-18 1997-03-17 Anvendelse av en insulinsensibilisator for fremstilling av et preparat for behandling og profylakse av pankreatitt NO313179B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6106396 1996-03-18
JP25020196 1996-09-20

Publications (3)

Publication Number Publication Date
NO971219D0 true NO971219D0 (no) 1997-03-17
NO971219L NO971219L (no) 1997-09-19
NO313179B1 NO313179B1 (no) 2002-08-26

Family

ID=26402115

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971219A NO313179B1 (no) 1996-03-18 1997-03-17 Anvendelse av en insulinsensibilisator for fremstilling av et preparat for behandling og profylakse av pankreatitt

Country Status (19)

Country Link
US (1) US5753681A (no)
EP (1) EP0796618B1 (no)
KR (1) KR100542778B1 (no)
CN (1) CN1178657C (no)
AT (1) ATE212548T1 (no)
AU (1) AU708315B2 (no)
CA (1) CA2200126C (no)
CZ (1) CZ283968B6 (no)
DE (1) DE69710111T2 (no)
DK (1) DK0796618T3 (no)
ES (1) ES2167678T3 (no)
HK (1) HK1003051A1 (no)
HU (1) HUP9700598A3 (no)
ID (1) ID16266A (no)
IL (1) IL120443A (no)
NO (1) NO313179B1 (no)
NZ (1) NZ314406A (no)
PT (1) PT796618E (no)
TW (1) TW548102B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
EP1022272B1 (en) * 1997-10-08 2004-05-26 Sankyo Company Limited Substituted fused heterocyclic compounds
EP0992503B1 (en) * 1998-03-30 2004-02-04 Japan Tobacco Inc. Process for producing isooxazolidinedione compound
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
BR9912117A (pt) * 1998-07-21 2001-04-10 Smithkline Beecham Plc Uso de estimulador de captação de glicose para reduzir a apoptose
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
CA2382574A1 (en) 1999-08-23 2001-03-01 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
KR100700304B1 (ko) 1999-08-23 2007-03-29 교린 세이야꾸 가부시키 가이샤 치환된 벤질티아졸리딘-2,4-디온 유도체
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
SG174891A1 (en) 2009-04-01 2011-11-28 Genentech Inc Treatment of insulin-resistant disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DE3343141A1 (de) * 1983-11-29 1985-06-05 Hermann P.T. 7400 Tübingen Ammon Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
NO893088L (no) * 1988-08-18 1990-02-19 Syntex Inc Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser.
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
WO1995002340A1 (en) * 1993-07-13 1995-01-26 Moizis Janica M Fastener for clothing
WO1995018125A1 (fr) * 1993-12-27 1995-07-06 Japan Tobacco Inc. Derive d'isoxazolidinedione et son utilisation
CA2146701A1 (en) * 1994-04-11 1995-10-12 Takashi Fujita Heterocyclic compounds having anti-diabetic activity, their preparation and their use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
FR2721608B1 (fr) * 1994-06-22 1996-07-19 Rhone Poulenc Rorer Sa Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
CZ261095A3 (en) * 1994-10-07 1996-04-17 Sankyo Co Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem

Also Published As

Publication number Publication date
NZ314406A (en) 2000-12-22
IL120443A (en) 2000-07-16
NO971219L (no) 1997-09-19
HK1003051A1 (en) 1998-10-09
ID16266A (id) 1997-09-18
DE69710111T2 (de) 2002-10-02
AU1628597A (en) 1997-09-25
HUP9700598A2 (hu) 1998-09-28
EP0796618B1 (en) 2002-01-30
KR100542778B1 (ko) 2006-04-14
NO313179B1 (no) 2002-08-26
EP0796618A1 (en) 1997-09-24
DE69710111D1 (de) 2002-03-14
ES2167678T3 (es) 2002-05-16
CZ283968B6 (cs) 1998-07-15
ATE212548T1 (de) 2002-02-15
TW548102B (en) 2003-08-21
MX9702058A (es) 1998-03-31
US5753681A (en) 1998-05-19
PT796618E (pt) 2002-06-28
CN1178657C (zh) 2004-12-08
HU9700598D0 (en) 1997-05-28
CA2200126A1 (en) 1997-09-18
CA2200126C (en) 2006-08-15
IL120443A0 (en) 1997-07-13
CN1170575A (zh) 1998-01-21
DK0796618T3 (da) 2002-05-06
KR19980023975A (ko) 1998-07-06
AU708315B2 (en) 1999-07-29
HUP9700598A3 (en) 1998-10-28
CZ79097A3 (en) 1997-10-15

Similar Documents

Publication Publication Date Title
NO971219L (no) Behandling og profylakse av pankreatitt
PL304649A1 (en) Novel derivatives of taxane and pharmaceutical agents
ZA954400B (en) Oxalylamino-benzofuran- and benzothienyl-derivatives
TR200200068T2 (tr) Nematisital triflüorobütenler
ATE253063T1 (de) 5-ht1f-agonisten
JPS5646809A (en) Glycolic acid oxidase inhibitor of 44*substituted thiazolyl**33hydroxyy33 pyrrolinee2*55dione
AU6452194A (en) Pharmaceutical agents for treatment of emesis
ES2127396T3 (es) Inhibidores aromaticos de acetilcolinesterasa.
NO304598B1 (no) Forgrenet-amino-substituerte tiazoler, anvendelse av dem og farmas°ytiske blandinger inneholdende dem
DK0684951T3 (da) Silylerede acetylcholinesterase-inhibitorer
DE69825605D1 (de) Behandlung der schizophrenie und der psychose
FI934395A0 (fi) 2-spirocyklopropyl 4-acylcephemi samt foerfarande foer framstaellning daerav
NO943765L (no) Aryloksybenzen-herbicidmidler
KR960702835A (ko) 헤테로사이클릭 화학(Heterocyclic chemistry)
DK0703916T3 (da) 14-Substituerede marcfortiner og derivater, der kan anvendes som antispirant-midler
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler